European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.
Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.
GE Healthcare has been no stranger to dealmaking over the past year, and the company's CEO said it has no plans to let up.
ERBA Diagnostics has something to crow about for 2013. Year-over-year, the Florida in vitro diagnostics outfit swung from a net loss to a small profit, aided, in part, by a surge in new revenue stemming from a 2012 acquisition. The company said it is eyeing more M&A deals in 2014.
Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.
NeoStem says it will acquire California Stem Cell and a Phase III-ready cancer immunotherapy.
Irish medical device giant Covidien has purchased Florida-based New Wave Surgical for more than $100 million.
Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its revamp by Sun might put them in peril.
With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.
Mention Ranbaxy drugs to some wholesalers and U.S. doctors these days, and they will respond negatively. And so the Ranbaxy brand looks to be on its way out when Sun Pharmaceutical completes its $3.2 billion acquisition of Ranbaxy Laboratories later this year.